Syria approves Russia's Sputnik Covid vaccine

coronavirus vaccine
Credit: Pixabay/CC0 Public Domain

Syria has authorised the use of Russia's Sputnik V coronavirus vaccine, its embassy in Moscow said Monday.

The country is the latest to approve the Russian , named after the Soviet-era satellite. Sputnik V was registered in August before clinical trials were underway, which left experts wary.

But leading The Lancet published results showing the jab to be safe and 91.6 percent effective.

"The Syrian Arab Republic has completed all registration procedures for the Russian Sputnik V vaccine against the and allowed its use on its territory," the Russian TASS news agency cited the Syrian embassy as saying in a statement.

More than 30 countries have approved the vaccine, according to the Russian Direct Investment Fund, which financed its development.

Syria in December also signed on to the World Health Organisation's Covax initiative to procure vaccines.

The WHO, together with the UN children's agency UNICEF and Gavi, will support Syria in acquiring jabs to initially cover at least three percent of the population and aim for 20 percent by the end of the year.

Syria has recorded 15,179 coronavirus infections and 998 fatalities from the virus in government-held areas.

Territories under Kurdish control in the country's northeast have recorded nearly 8,600 cases and 311 deaths, while the rebel-held northwest has reported 21,121 infections and 408 fatalities.

Russia backs Syrian President Bashar al-Assad in the country's long-running civil war.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

Journal information: The Lancet

© 2021 AFP

Citation: Syria approves Russia's Sputnik Covid vaccine (2021, February 22) retrieved 4 March 2021 from https://medicalxpress.com/news/2021-02-syria-russia-sputnik-covid-vaccine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments